Fatty acid synthase: A target for the reversal of liver steatosis

Current Enzyme Inhibition

Volumn 4, Issue 3, 2008, Pages 100-108

  Evans, Zachary P ^a   Ellett, Justin D ^a   Chavin, Kenneth D ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE   (United States)

Author keywords

Cerulenin; EGCG; Fatty acid synthase liver; Fatty liver disease; Steatosis; Transplantation

Indexed keywords

3 CARBOXY 4 ALKYL 2 METHYLENEBUTYROLACTONE; ACETYL COENZYME A CARBOXYLASE; C 75; CERULENIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN A; EPIGALLOCATECHIN GALLATE; FATTY ACID; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; GREEN TEA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 1BETA; MALONYL COENZYME A; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TAMOXIFEN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALCOHOL ABUSE; BARIATRIC SURGERY; CELL LEVEL; CYTOTOXICITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME REPRESSION; FAT CONTENT; FATTY ACID OMEGA OXIDATION; FATTY ACID OXIDATION; FATTY LIVER; HUMAN; KUPFFER CELL; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIPID PEROXIDATION; LIPID STORAGE; LIPOPROTEIN SYNTHESIS; LIVER CELL; LIVER FUNCTION; LIVER ISCHEMIA; LIVER TRANSPLANTATION; NONHUMAN; OBESITY; PATHOGENESIS; PREOPERATIVE CARE; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; UPREGULATION; WEIGHT REDUCTION;

EID: 54949143224     PISSN: 15734080     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340808785909376     Document Type: Review

References (80)

1. D'Alessandro, A.M.; Kalayoglu, M.; Sollinger, H. W.; Hoffmann, R.M.; Reed, A.; Knechtle, S.J.; Pirsch, J.D.; Hafez, G.R.; Lorentzen, D.; Belzer, F.O. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation, 1991, 51, 157-163.
2. Marsman, W.A.; Wiesner, R.H.; Rodriguez, L.; Batts, K.P.; Porayko, M.K.; Hay, J.E.; Gores, G.J.; Krom, R.A. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation, 1996, 62, 1246-1251.
3. Cave, M.; Deaciuc, I.; Mendez, C.; Song, Z.; Joshi-Barve, S.; Barve, S.; McClain, C. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J. Nutr. Biochem., 2007, 18, 184-195.
4. Wilfred de Alwis, N.M.; Day, C.P. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin. Liver Dis., 2007, 27, 44-54.
5. Harrison, S.A.; Torgerson, S.; Hayashi, P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am. J. Gastroenterol., 2003, 98, 2042-2047.
6. Kooby, D.A.; Fong, Y.; Suriawinata, A.; Gonen, M.; Allen, P.J.; Klimstra, D.S.; DeMatteo, R.P.; D'Angelica, M.; Blumgart, L.H.; Jarnagin, W.R. Impact of steatosis on perioperative outcome following hepatic resection. J. Gastrointest. Surg., 2003, 7, 1034-1044.
7. Selzner, M.; Clavien, P.A. Fatty liver in liver transplantation and surgery. Semin. Liver Dis., 2001, 21, 105-113.
8. Jaeschke, H.; Gores, G.J.; Cederbaum, A.I.; Hinson, J.A.; Pessayre, D.; Lemasters, J.J. Mechanisms of hepatotoxicity. Toxicol. Sci., 2002, 65, 166-176.
9. Szczepaniak, L.S.; Nurenberg, P.; Leonard, D.; Browning, J.D.; Reingold, J.S.; Grundy, S.; Hobbs, H.H.; Dobbins, R.L. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab., 2005, 288, E462-468.
10. Sheth, S.G.; Gordon, F.D.; Chopra, S. Nonalcoholic steatohepatitis. Ann. Intern. Med., 1997, 126, 137-145.
11. Donnelly, K.L.; Smith, C.I.; Schwarzenberg, S.J.; Jessurun, J.; Boldt, M.D.; Parks, E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest., 2005, 115, 1343-1351.
12. Reddy, J.K.; Hashimoto, T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr., 2001, 21, 193-230.
13. Tolwani, R.J.; Hamm, D.A.; Tian, L.; Sharer, J.D.; Vockley, J.; Rinaldo, P.; Matern, D.; Schoeb, T.R.; Wood, P.A. Medium-chain acyl-CoA dehydrogenase deficiency in gene-targeted mice. PLoS Genet., 2005, 1, e23.
14. Ploeg, R.J.; D'Alessandro, A.M.; Knechtle, S.J., Stegall, M.D.; Pirsch, J.D.; Hoffmann, R.M.; Sasaki, T., Sollinger, H.W., Belzer, F.O.; Kalayoglu, M. Risk factors for primary dysfunction after liver transplantation - a multivariate analysis. Transplantation, 1993, 55, 807-813.
15. Markin, R.S.; Wisecarver, J.L.; Radio, S.J.; Stratta, R.J.; Langnas, A.N.; Hirst, K.; Shaw, B.W.; Jr. Frozen section evaluation of donor livers before transplantation. Transplantation, 1993, 56, 1403-1409. 16 Fiorini, R.N.; Kirtz, J.; Periyasamy, B.; Evans, Z.; Haines, J.K.; Cheng, G.; Polito, C.; Rodwell, D.; Shafizadeh, S.F.; Zhou, X.; Campbell, C.; Birsner, J.; Schmidt M.; Lewin, D.; Chavin, K.D. Development of an unbiased method for the estimation of liver steatosis. Clin. Transplant., 2004, 18, 700-706.
16. Fukumori, T.; Ohkohchi, N.; Tsukamoto, S.; Satomi, S. The mechanism of injury in a steatotic liver graft during cold preservation. Transplantation, 1999, 67, 195-200.
17. Seifalian, A.M.; Piasecki, C.; Agarwal, A.; Davidson, B.R. The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation, 1999, 68, 780-784.
18. Taneja, C.; Prescott, L.; Koneru, B. Critical preservation injury in rat fatty liver is to hepatocytes, not sinusoidal lining cells. Transplantation, 1998, 65, 167-112.
19. McCuskey, R.S.; Ito, Y.; Robertson, G.R; McCuskey, M.K.; Perry, M.; Farrell, G.C. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology, 2004, 40, 386-393.
20. Sun, C.K.; Zhang, X.Y.; Zimmermann, A.; Davis, G.; Wheatley, A.M. Effect of ischemia-reperfusion injury on the microcirculation of the steatotic liver of the Zucker rat. Transplantation, 2001, 72, 1625-1631.
21. Wasserman, D.H.; Cherrington, A.D. Hepatic fuel metabolism during muscular work: role and regulation. Am. J. Physiol., 1991, 260, E811-824.
22. Zhong, Z.; Connor, H.D.; Mason, R.P.; Lemasters, J.J.; Thurman, R.G. Ethanol, not fat accumulation per se, increases free radical production in a low-flow, reflow liver perfusion model. Transplantation, 1998, 66, 1431-1438.
23. Caldwell-Kenkel, J.C.; Currin, R.T.; Tanaka, Y.; Thurman, R.G.; Lemasters, J.J. Kupffer cell activation and endothelial cell damage after storage of rat livers: effects of reperfusion. Hepatology, 1991, 13, 83-95.
24. Kozaki, K.; Matsuno, N.; Kozaki, M. Beneficial effects of pentoxifylline and propentofylline on preservation-reperfusion injury in rat liver transplantation. Transplant Proc., 1996, 28, 333-334.
25. Hakamada, K.; Sasaki, M.; Takahashi, K.; Umehara, Y.; Konn, M. Sinusoidal flow block after warm ischemia in rats with diet-induced fatty liver. J. Surg. Res., 1997, 70, 12-20.
26. Sato, N.; Eguchi, H.; Inoue, A.; Matsumura, T.; Kawano, S.; Kamada, T. Hepatic microcirculation in Zucker fatty rats. Adv. Exp. Med. Biol., 1986, 200, 477-483.
27. Selzner, M.; Rudiger, H.A.; Sindram, D.; Madden, J.; Clavien, P.A. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology, 2000, 32, 1280-1288.
28. Caraceni, P.; Ryu, H.S.; Subbotin, V.; De Maria, N.; Colantoni, A,; Roberts, L.; Trevisani, F.; Bernardi, M.; Van Thiel, D.H. Rat hepatocytes isolated from alcohol-induced fatty liver have an increased sensitivity to anoxic injury. Hepatology, 1997, 25, 943-949.
29. Ferguson, D.M.; Gores, G.J.; Ludwig, J.; Krom, R.A. UW solution protects against reperfusion injury by inhibiting lipid peroxidation. Transplant Proc., 1991, 23, 1552-1553.
30. Gao, W.; Connor, H.D.; Lemasters, J.J.; Mason, R.P.; Thurman, R.G. Primary nonfunction of fatty livers produced by alcohol is associated with a new, antioxidant-insensitive free radical species. Transplantation, 1995, 59, 674-679.
31. Kanno, M.; Ohkohchi, N.; Terashima, T.; Seya, K.; Taguchi, Y.; Mori, S.; Inaba, H. Lipid peroxidatron of parenchymal hepatocytes during cold preservation and after reoxygenation in rats. Transplant Proc., 1993, 25, 2716-2721.
32. Tsoulfas, G.; Takahashi, Y.; Ganster, R.W.; Yagnik, G.; Guo, Z.; Fung, J.J.; Murase, N.; Geller, D. A. Activation of the lipopolysaccharide signaling pathway in hepatic transplantation preservation injury. Transplantation, 2002, 74, 7-13.
33. Yang, S.Q.; Lin, H.Z.; Lane, M.D.; Clemens, M, Drebl, A.M. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Prod. Natl. Acad. Sci. USA, 1997, 94, 2557-2562.
34. Wanner, G.A.; Ertel, W.; Muller, P.; Hofer, Y.; Leiderer, R; Menger, M.D.; Messmer, K. Liver ischemia and reperfusion induces a systemic inflammatory response through Kupffer cell activation. Shock, 1996, 5, 34-40.
35. Jaeschke, H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am. J. Physiol. Gastrointest. Liver Physiol., 2003, 284, G15-26.
36. Rudiger, H.A.; Clavien, P.A. Tumor necrosis factor alpha, but not Fas, mediates hepatocellular apoptosis in the murine ischemic liver. Gastroenterology, 2002, 122, 202-210.
37. Teoh, N.; Field, J.; Sutton, J.; Farrell, G. Dual role of tumor necrosis factor-alpha in hepatic ischemia-reperfusion injury: studies in tumor necrosis factor-alpha gene knockout mice. Hepatology, 2004, 39, 412-421.
38. Teoh, N.; Leclercq, I.; Pena, A.D.; Farrell, G. Low-dose TNF-alpha protects against hepatic ischemia-reperfusion injury in mice: implications for preconditioning. Hepatology, 2003, 37, 118-128.
39. Evans, Z.P.; Ellett, J.D.; Schmidt, M.G.; Schnellmann, R.G.; Chavin, K.D. Mitochondrial uncoupling protein-2 mediates steatotic liver injury following ischemia/reperfusion. J. Biol. Chem., 2008, 283, 8573-8579.
40. Fiorini, R.N.; Shafizadeh, S.F.; Polito, C.; Rodwell, D.W.; Cheng, G.; Evans, Z.; Wan, C.; Belden, S.; Haines, J.K.; Birsner, J.; Lewin, D; Wasiluk, K.R.; Dunn, D.L.; Schmidt, M.G.; Chavin, K. D. Anti-endotoxin monoclonal antibodies are protective against hepatic ischemia/ reperfusion injury in steatotic mice. Am. J. Transplant. 2004, 4, 1567-1573.
41. Smith, S. The animal fatty acid synthase: one gene, one polypeptide, seven enzymes. Faseb J., 1994, 8, 1248-1259.
42. Lupu, R.; Menendez, J.A. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr. Phram. Biotechnol., 2006, 7, 483-493.
43. Heath, R.J.; White, S.W.; Rock, C.O. Lipid biosynthesis as a target for antibacterial agents. Prog. Lipid Res., 2001, 40, 467-497.
44. Loftus, T.M.; Jaworsky, D.E.; Frehywot, G.L.; Townsend, C.A.; Ronnett, G.V.; Lane, M.D.; Kuhajda, F.P. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science, 2000, 288, 2379-2381.
45. Deeney, J.T.; Gromada, J.; Hoy, M.; Olsen, H.L.; Rhodes, C.J.; Prentki, M.; Berggren, P.O.; Corkey, B. E. Acute stimulation with long chain acyl-CCA enhances exocytosis in insulin-secreting cells (HIT T-15 and NMRI beta-cells). J. Biol. Chem., 2000, 275, 9363-9368.
46. Parrish, N.M.; Kuhajda, F.P.; Heine, H.S.; Bishai, W.R.; Dick, J.D. Antimycobacterial activity of cerulenin and its effects on lipid biosynthesis. J. Antimicrob. Chemother., 1999, 43, 219-226.
47. Menendez, J.A.; Lupu, R.; Colomer, R. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neuoverexpressing breast cancer. Drug News Perspect., 2005, 18, 375-385.
48. Geerts, D.; Wallick, C.J.; Koomoa, D.L.; Koster, J.; Versteeg, R.; Go, R.C.; Bachmann, A.S. Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation. Clin. Cancer Res., 2007, 13, 6312-6319.
49. Ho, T.S.; Ho, Y.P.; Wong, W.Y.; Chi-Ming Chiu, L.; Wong, Y.S.; Eng-Choon Ooi, V. Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma. Biomed. Pharmacother., 2007, 61, 578-587.
50. Okawa, Y.; Hideshima, T.; Ikeda, H.; Raje, N.; Vallet, S.; Kiziltepe, T.; Yasui, H.; Enatsu, S.; Pozzi, S.; Breitkreutz, I.; Cirstea, D.; Santo, L.; Richardson, P.; Anderson, K.C. Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br. J. Haematol., 2008, 141, 659-671.
51. Zhang, Y.; Guo, C.; Yu, G. A pilot study of fatty acid metabolism in oral squamous cell carcinoma. Int. J. Oral Maxillofac. Surg., 2005, 34, 78-81.
52. Kuhajda, F.P.; Pizer, E.S.; Li, J.N.; Mani, N.S.; Frehywot, G.L.; Townsend, C.A. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc. Natl. Acad. Sci. USA, 2000, 97, 3450-3454.
53. Rendina, A.R.; Cheng, D. Characterization of the inactivation of rat fatty acid synthase by C75: inhibition of partial reactions and protection by substrates. Biochem. J., 2005, 388, 895-903.
54. Ronnett, G.V.; Kim, E.K.; Landree, L.E. and Tu, Y. Fatty acid metabolism as a target for obesity treatment. Physiol. Behav., 2005, 85, 25-35.
55. Cha, S.H.; Hu, Z.; Lane, M.D. Long-term effects of a fatty acid synthase inhibitor on obese mice: food intake, hypothalamic neuropeptides, and UCP3. Biochem. Biophys. Res. Commun., 2004, 317, 301-308.
56. Shimokawa, T.; Kumar, M.V.; Lane, M.D. Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides. Proc. Natl. Acad. Sci. USA, 2002, 99, 66-71.
57. Wang, X.; Tian, W. Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem. Biophys. Res. Commun., 2001, 288, 1200-1206.
58. Bentebibel, A.; Sebastian, D.; Herrero, L.; Lopez-Vinas, E.; Serra, D.; Asins, G.; Gomez-Puertas, P.; Hegardt, F.G. Novel effect of C75 on carnitine palmitoyltransferase I activity and palmitate oxidation. Biochemistry, 2006, 45, 4339-4350.
59. Horiguchi, A.; Asano, T.; Ito, K.; Sumitomo, M.; Hayakawa, M. Pharmacological Inhibitor of Fatty Acid Synthase Suppresses Growth and Invasiveness of Renal Cancer Cells. J. Urol., 2008, 180(3), 1137-1140.
60. Orita, H.; Coulter, J.; Tully, E.; Kuhajda, F.P.; Gabrielson, E. Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors. Clin. Cancer Res., 2008, 14, 2458-2464.
61. Dona, M.; Dell'Aica, I.; Calabrese, F.; Benelli, R.; Morini, M.; Albini, A.; Garbisa, S: Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J. Immunol., 2003, 170, 4335-4341.
62. Kavanagh, K.T.; Hafer, L.J.; Kim, D.W.; Mann, K.K.; Sherr, D.H.; Rogers, A.E.; Sonenshein, G.E. Green tea extracts decrease carcinogen-induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. J. Cell Biochem., 2001, 82, 387-398.
63. Wolfram, S.; Raederstorff D.; Wang, Y.; Teixeira, S.R.; Elste, V.; Weber, P. TEAVIGO (epigallocatechin gallate) supplementation prevents obesity in rodents by reducing adipose tissue mass. Ann. Nutr. Metab., 2005, 49, 54-63.
64. Zhang, R.; Xiao, W.; Wang, X.; Wu, X.; Tian, W. Novel inhibitors of fatty-acid synthase from green tea (Camellia sinensis Xihu Longjing) with high activity and a new reacting site. Biotechnol. Appl. Biochem., 2006, 43, 1-7.
65. Moon, H.S.; Lee, H.G.; Choi, Y.J.; Kim, T.G.; Cho, C.S. Proposed mechanisms of (-)-epigallocatechin-3-gallate for anti-obesity. Chem. Biol. Interact., 2007, 167, 85-98.
66. Collins, Q.F.; Liu, H.Y.; Pi, J.; Liu, Z.; Quon, M.J.; Cao, W. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5′-AMP-activated protein kinase. J. Biol. Chem., 2007, 282, 30143-30149.
67. Giakoustidis, A.E.; Giakoustidis, D.E.; Koliakou, K.; Kaldrymidou, E.; Iliadis, S.; Antoniadis, N.; Kontos, N.; Papanikolaou, V.; Papageorgiou, G.; Atmatzidis, K.; Takoudas, D. Inhibition of intestinal ischemia/ repurfusion induced apoptosis and necrosis via downregulation of the NF-kB, c-Jun and caspace-3 expression by epigallocatechin-3-gallate administration. Free Radic. Res., 2008, 42, 180-188.
68. Yao, K.; Ye, P.; Zhang, L.; Tan, J.; Tang, X.; Zhang, Y. Epigallocatechin gallate protects against oxidative stress-induced mitochondria-dependent apoptosis in human lens epithelial cells. Mol. Vis., 2008, 14, 217-223.
69. Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med., 2002, 346, 1221-1231.
70. Clavien, P.A.; Harvey, P.R.; Strasberg, S.M. Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies. Transplantation, 1992, 53, 957-978.
71. Azoulay, D.; Del Gaudio, M.; Andreani, P.; Ichai, P.; Sebag, M.; Adam, R.; Scatton, O.; Min, B.Y.; Delvard, V.; Lemoine, A.; Bismuth, H.; Castaing, D. Effects of 10 minutes of ischemic preconditioning of the cadaveric liver on the graft's preservation and function: the ying and the yang. Ann. Surg., 2005, 242, 133-139.
72. Drenick, E.J.; Simmons, F.; Murphy, J.F. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N. Engl. J. Med., 1970, 282, 829-834.
73. Kuzu, N.; Bahcecioglu, I.H.; Dagli, A.F.; Ozercan, I.H.; Ustundag, B.; Sahin, K. Epigallocatechin gallate attenuates experimental non-alcoholic steatohepatitis induced by high fat diet. J. Gastroenterol. Hepatol., 2007, 23(8 Pt 2), e465-470.
74. Zhen, M.C.; Wang, Q.; Huang, X.H.; Cao, L.Q.; Chen, X.L.; Sun, K.; Liu, Y.J.; Li, W.; Zhang, L.J. Green tea polyphenol epigallocatechin-3-gallate inhibits oxidative damage and preventive effects on carbon tetrachloride-induced hepatic fibrosis. J. Nutr. Biochem., 2007, 18, 795-805.
75. Chavin, K.D.; Fiorini, R.N.; Shafizadeh, S.; Cheng, G.; Wan, C.; Evans, Z.; Rodwell, D.; Paulo, C.; Haines, J.K.; Baillie, G.M.; Schmidt, M.G. Fatty acid synthase blockade protects steatotic livers from warm ischemia reperfusion injury and transplantation. Am. J. Transplant., 2004, 4, 1440-1447.
76. Fiorini, R.N.; Donovan, J.L.; Rodwell, D.; Evans, Z.; Cheng, G.; May, H.D.; Milliken, C.E.; Markowitz, J.S.; Campbell, C.; Haines, J.K.; Schmidt, M.G.; Chavin, K.D. Short-term administration of (-)-epigallocatechin gallate reduces hepatic steatosis and protects against warm hepatic ischemia/reperfusion injury in steatotic mice. Liver Transpl., 2005, 11, 298-308.
77. Dentin, R.; Benhamed, F.; Hainault, I.; Fauveau, V.; Foufelle, F.; Dyck, J.R.; Girard, J.; Panic, C. Liver-Specific Inhibition of ChREBP Improves Hepatic Steatosis and Insulin Resistance in ob/ob Mice. Diabetes, 2006, 55, 2159-2170.
78. Lelliott, C.J.; Lopez, M.; Curtis, R.K., Parker, N.; Laudes, M.; Yeo, G.; Jimenez-Linan, M.; Grosse, J.; Saha, A.K.; Wiggins, D.; Hauton, D.; Brand, M.D.; O'Rahilly, S.; Griffin, J.L.; Gibbons, G.F.; Vidal-Puig, A. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J., 2005, 19, 1108-1119.
79. Wang, Y.; Zhang, S.Y.; Ma, X.F.; Tian, W.X. Potent inhibition of fatty acid synthase by parasitic loranthus [Taxillus chinensis (dc.) danser] and its constituent avicularin. J. Enzyme Inhtb. Med. Chem., 2006, 21, 87-93.
80. Lupu, R.; Colomer, R.; Menendez, J.A. An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic antigen-519) modulators with potential anticancer value. Clin. Transl. Oncol., 2008, 10, 219-226.